Anthracycline-containing regimens for treatment of follicular lymphoma in adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Itchaki, Gilad ^a   Gafter Gvili, Anat ^a   Lahav, Meir ^a   Vidal, Liat ^a   Raanani, Pia ^a   Shpilberg, Ofer ^a   Paul, Mical ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC; MONOCLONAL ANTIBODY;

ALOPECIA; BIBLIOGRAPHIC DATABASE; BONE MARROW SUPPRESSION; CANCER CONTROL; CARDIOTOXICITY; CYTOPENIA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INFECTION; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; ADULT; INDUCTION CHEMOTHERAPY; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; MORTALITY; PATHOLOGY; PROCEDURES; METHODOLOGY;

ADULT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, FOLLICULAR; MAINTENANCE CHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITUXIMAB;

EID: 84891643338     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008909.pub2     Document Type: Review

References (96)

1. Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology 2013;31(12):1506-13.
2. Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, et al. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer 1983;51(6):1083-90.
3. Kimby E, Bjorkholm M, Gahrton G, Glimelius B, Hagberg H, Johansson B, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Annals of Oncology 1994;5 Suppl 2:67-71.
4. Lepage E, Sebban C, Gisselbrecht C, Coiffier B, Harousseau JL, Bryon PA, et al. Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematological Oncology 1990;8(1):31-9.
5. Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. Journal of Clinical Oncology 2003;21(1):5-15.
6. Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia & Lymphoma 2006;47(11):2321-30.
7. Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trumper L, et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996;10(5):836-43.
8. Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. Journal of Clinical Oncology 2000;18(4):773-9.
9. Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA. Histologic conversion in the non-Hodgkin's lymphomas. Journal of Clinical Oncology 1983;1(1):11-6.
10. Al-Ismail SA, Whittaker JA, Gough J. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma. European Journal of Cancer & Clinical Oncology 1987;23(9):1379-84.
11. Andersen J, Thorling K, Bentzen SM, Brincker H, Christensen BE, Pedersen M. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group. Acta Oncologica 1990;29(8):995-9.
12. Ben-Shahar M, Gepstein R, Haim R, Polliack A. Phase III trial of a combination of chlorambucil (L) and prednisone (P) with or without mitoxantrone (M) in advanced low grade non-Hodgkin's lymphoma (NHL) and CLL. Proceedings of the American Society of Clinical Oncology (Annual Meeting of the American Society of Clinical Oncology). Los Angeles, CA: Annual Meeting of the American Society of Clinical Oncology, 1998; Vol. 17:20a Abstract No 75.
13. Bonadonna G, De Lena M, Lattuada A, Milani F, Monfardini S, Beretta G. Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata. The British Journal Cancer. Supplement 1975;2:481-8.
14. Cabanillas F, Rodriguez V, Freireich EJ. Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. Medical and Pediatric Oncology 1978;4(4):321-31.
15. Coiffier B, Neidhardt-Berard EM, Tilly H, Belanger C, Bouabdallah R, Haioun C, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of Oncology 1999;10(10):1191-7.
16. Engelhard M, Bartels H, Binder T, Fulle HH, Gunzer U, Havemann K, et al. Multicenter randomized trial of the polychemotherapy of advanced centrocytic lymphoma: no prognostic advantage by anthracycline. Blut 1986;53(3):220.
17. Flinn EW, Van der Jagt RH, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The BRIGHT Study. Blood (ASH Annual Meeting Abstracts) 2012;120(21):Abstract No 902.
18. Gad EMN. Chemotherapeutic management of non Hodgkin's lymphoma: comparative study of various combinations. Chemotherapy - Proceedings of the 9th International Congress of Chemotherapy. New York: Plenum press, 1976; Vol. 2:581-3.
19. Gams RA, Rainey M, Dandy M, Bartolucci AA, Silberman H, Omura G. Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. Journal of Clinical Oncology 1985;3(9):1188-95.
20. Gisselbrecht C, Lepage E, Sebban C, Coiffier B. Low-grade non-Hodgkin's lymphoma in the adult: new therapeutic approaches [Lymphome non hodgkinien de l'adulte de faible evolutivite: nouvelles approches therapeutiques]. Nouvelle Revue Francaise d'Hematologie 1987;29(1):77-81.
21. Ha CS, Cabanillas F, Lee MS, Tucker SL, McLaughlin P, Rodriguez MA, et al. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. International Journal of Radiation Oncology, Biology, Physics 2005;63(1):188-93.
22. Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology 2005;23(7):1500-6.
23. Hiddemann W, Unterhalt M, Koch P, Nahler M, Herrmann R. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only - a preliminary update of the German Low-Grade Lymphoma Study Group. Seminars in Hematology 1994;31 Suppl 3(2):32-5.
24. Hiddemann W, Unterhalt M, Herrmann R, Woltjen HH, Kreuser ED, Trumper L, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. Journal of Clinical Oncology 1998;16(5):1922-30.
25. Inoue T, Fujiyama Y, Kitoh K, Niwakawa M, Andoh A, Hodohara K, et al. Effect of combination chemotherapy for elderly patients with malignant lymphoma. Nippon Ronen Igakkai Zasshi 1993;30(10):864-8.
26. Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, et al. Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer 1979;43(2):417-25.
27. Junmin L. Fludarabine-based regimens in the treatment of indolent non-Hodgkin's lymphoma patients: a clinical study of the Fludarabine Cooperation Group in 16 hospitals in Eastern China. Blood (ASH Annual Meeting Abstracts) 2005;106:Abstract No 4753.
28. Meerwaldt JH, Carde P, Burgers JM, Monconduit M, Thomas J, Somers R, et al. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. International Journal of Radiation Oncology, Biology, Physics 1991;21(5):1167-72.
29. Meusers P, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg K, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematological Oncology 1989;7(5):365-80.
30. Mukherji D, Pettengell R. Pixantrone maleate for non-Hodgkin's lymphoma. Drugs Today (Barc) 2009;45(11):797-805.
31. Niitsu N, Umeda M. Prognostic factors of follicular lymphoma treated with combination chemotherapy. Rinsho Ketsueki [The Japanese Journal of Clinical Hematology] 1997;38(6):496-504.
32. Parlier Y, Gorin NC, Stachowiak J, Najman A, Duhamel G. Adriamycin for the treatment of non Hodgkin's lymphomas [Interet de l'adriamycine dans le traitement des lymphomes non Hodgkiniens]. La Seminae de Hospitaux 1981;57(41-42):1685-90.
33. Parlier Y, Gorin NC, Najman A, Stachowiak J, Duhamel G. Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases. Cancer 1982;50(3):401-9.
34. Peterson BA, Anderson JR, Frizzera G, Bloomfield CD, Gottlieb AJ, Holland JF. Nodular mixed lymphoma (NML): a comparative trial of cyclophosphamide adriamycin vincristine prednisone and bleomycin (CAVPB). Blood 1985;5 Suppl 1:216a.
35. Pettengell R, Narayanan G, Mendoza FH, Digumarti R, Gomez H, Cernohous P, et al. Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology (ASCO Annual Meeting) 2009;27(15s):Abstract No 8523.
36. Pott C, Unterhalt M, Sandford D, Markert H, Freund M, Engert A, et al. Fludarabine as single agent and in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin-lymphoma. Annals of Hematology 1994;68 Suppl 1:A2.
37. Prentice AG, Johnson SAN, Harper M, Hewins P, Tyrrell CJ, Copplestone JA, et al. A randomised, prospective trial of chlorambucil and prednisolone (CP) v mitozantrone, chlorambucil and prednisolone (MCP) in de novo, stage II or more advanced, low-grade non-Hodgkins lymphoma (LG-NHL). British Journal of Haematology (Annual Meeting of the British Society for Haematology) 1996;93 Suppl 1:74 Abstract No 286.
38. Robak T, Gora-Tybor J, Chojnowski K. Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies. Haematologica 2000;85(2):215-6.
39. Rummel MJ. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. Seminars in Hematology 2008;45 Suppl 2(3):S7-10.
40. Rummel MJ, von Gruenhagen U, Niederle N, Ballo H, Weidmann E, Welslau M, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-Line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL). Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract No 2596.
41. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10.
42. Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM, et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001;86(3):282-6.
43. Santoro A, Voglova J, Gabrail N, Ciuleanu T, Liberati M, Hancock BW, et al. Comparative trial of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology (ASCO Annual Meeting Proceedings) 2006;24 Suppl(18):Abstract No 7578.
44. Somers R, Burgers JM, Qasim M, Van Glabbeke M, Duez N, Hayat M. EORTC trial non-Hodgkin lymphomas. European Journal of Cancer & Clinical Oncology 1987;23(3):283-93.
45. Unterhalt M, Koch P, Pfreundschuh M, Maschmeyer G, Freund M, Thiel F, et al. Prednimustine, mitoxantrone (PMM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low grade non-Hodgkin's lymphoma. Blood 1994;84 Suppl 1:Abstract No 656.
46. Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 1993;71(7):2342-50.
47. Young RC, Johnson RE, Canellos GP, Chabner BA, Brereton HD, Berard CW, et al. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treatment Reports 1977;61(6):1153-9.
48. NCT00551239 Fludarabine and rituximab with or without pixantrone in treating patients with relapsed or refractory indolent non-Hodgkin lymphoma. ClinicalTrials.gov/show/NCT00551239 (accessed 17 April 2013).
49. NCT00801281 First-line R-CVP vs R-CHOP induction immunochemotherapy for indolent lymphoma and R maintenance (PLRG4). ClinicalTrials.gov/show/NCT00801281 (accessed 17 April 2013).
50. Bartlett NL, Rizeq M, Dorfman RF, Halpern J, Horning SJ. Follicular large-cell lymphoma: intermediate or low grade?. Journal of Clinical Oncology 1994;12(7):1349-57.
51. Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA: A Cancer Journal for Clinicians 2008;58(5):305-17.
52. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatments Reports 1978;62(6):865-72.
53. Brandt L, Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncologica 2001;40(2-3):213-23.
54. Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leukemia & Lymphoma 2008;49 Suppl 1:18-26.
55. Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. British Journal of Cancer 2003;89(1):36-42.
56. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology 1999;17(4):1244.
57. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology 2007;25(5):579-86.
58. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. Journal of Clinical Oncology 1993;11(4):644-51.
59. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95(3):783-9.
60. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of Clinical Oncology 2009;27(27):4555-62.
61. Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology 2009;27(8):1202-8.
62. Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Annals of Oncology 2006;17(6):920-7.
63. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006.
64. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004024.pub2]
65. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A Revised European-American classification of Lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84(5):1361-92.
66. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999;17(12):3835-49.
67. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
68. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine 1984;311(23):1471-5.
69. Lister TA, Cullen MH, Beard ME, Brearley RL, Whitehouse JM, Wrigley PF, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1978;1(6112):533-7.
70. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology 2006;24(10):1582-9.
71. Mann RB, Berard CW. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematology and Oncology 1983;1(2):187-92.
72. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207-14.
73. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. Journal of Clinical Oncology 2007;25(17):2426-33.
74. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107(1):265-76.
75. Nabhan C. It is follicular... so, why CHOP?. Journal of Clinical Oncology 2007;25(7):915-6.
76. NHLCP A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89(11):3909-18.
77. Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. American Journal of Hematology 2010;85(4):255-60.
78. Outomuro D, Grana DR, Azzato F, Milei J. Adriamycin-induced myocardial toxicity: new solutions for an old problem?. International Journal of Cardiology 2007;117(1):6-15.
79. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
80. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5, 2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
81. Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leukemia & Lymphoma 2003;44(11):1911-7.
82. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51.
83. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003805.pub2]
84. Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. Journal of Hematology and Oncology 2009;2:14.
85. Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. New England Journal of Medicine 1993;329(22):1608-14.
86. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-65.
87. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. Vol. 2, Lyon, France: IARC Press, 2008.
88. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
89. Tilly H, Zelenetz A. Treatment of follicular lymphoma: current status. Leukemia & Lymphoma 2008;49 Suppl 1:7-17.
90. van Dalen EC, van der Pal HJ, Caron HN, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD005008.pub3]
91. Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006552.pub2]
92. Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Critical Reviews in Oncology/Hematology 2008;66(3):248-61.
93. Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D, et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1997;15(4):1654-63.
94. Williamson P, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21:3337-51.
95. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
96. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. Journal of Clinical Oncology 2004;22(13):2654-61.